



Aurobindo Pharma receives three new registrations from MCC – South Africa

Aurobindo Pharma Ltd is pleased to announce that it has received registrations from the Medicines Control Council (MCC) to manufacture and market 3 products in South Africa.

The products approved are as follows:

#	Product Name	Dosage Form	Active Ingredient	Category
1	AURO-CEFEPIME 500mg, 1000mg & 2000mg	Injectible	Cefepime 500mg, 1000mg & 2000mg	Anti-infective
2	LOXIP 250 mg & 500 mg	Tablet	Ciprofloxacin 250 mg & 500mg	Anti-infective
3	KEYSAL 5 mg & 10mg	Tablet	Amlodipine 5 mg & 10mg	CVS

Aurobindo now has a total of 41 registrations approved by the MCC.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com